Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers:
SEC Accession No. 0001628280-25-008647
Filing Date
2025-02-27
Accepted
2025-02-27 16:11:43
Documents
21
Effectiveness Date
2025-02-27

Document Format Files

Seq Description Document Type Size
1 S-3ASR denalitherapeuticss-3asrx2.htm S-3ASR 323785
2 dnlifilingfees.htm   iXBRL EX-FILING FEES 46358
3 EX-1.2 exhibit12-sx3asr22725.htm EX-1.2 267920
4 EX-4.2 exhibit42-sx3asr22725.htm EX-4.2 377853
5 EX-5.1 exhibit51-sx3asr22725.htm EX-5.1 27777
6 EX-23.2 exhibit232-sx3asr22725.htm EX-23.2 2389
7 dnlilogoa.jpg GRAPHIC 5258
8 wilsonsonsiniloga2aa.jpg GRAPHIC 363953
9 wilsonsonsinilogo1aa.jpg GRAPHIC 362252
  Complete submission text file 0001628280-25-008647.txt   2228317

Data Files

Seq Description Document Type Size
23 EXTRACTED XBRL INSTANCE DOCUMENT dnlifilingfees_htm.xml XML 15167
Mailing Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Business Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 (650) 866-8547
Denali Therapeutics Inc. (Filer) CIK: 0001714899 (see all company filings)

EIN.: 463872213 | State of Incorp.: DE | Fiscal Year End: 1231
Type: S-3ASR | Act: 33 | File No.: 333-285326 | Film No.: 25678858
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)